Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Liabilities and Shareholders Equity: 2011-2024

Historic Liabilities and Shareholders Equity for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $488.7 million.

  • Adma Biologics' Liabilities and Shareholders Equity rose 45.59% to $568.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 46.94%. This contributed to the annual value of $488.7 million for FY2024, which is 48.45% up from last year.
  • Adma Biologics' Liabilities and Shareholders Equity amounted to $488.7 million in FY2024, which was up 48.45% from $329.2 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Liabilities and Shareholders Equity ranged from a high of $488.7 million in FY2024 and a low of $207.7 million during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $348.5 million (2022), whereas its average is $388.8 million.
  • In the last 5 years, Adma Biologics' Liabilities and Shareholders Equity decreased by 5.53% in 2023 and then spiked by 48.45% in 2024.
  • Yearly analysis of 5 years shows Adma Biologics' Liabilities and Shareholders Equity stood at $207.7 million in 2020, then skyrocketed by 33.02% to $276.3 million in 2021, then grew by 26.14% to $348.5 million in 2022, then declined by 5.53% to $329.2 million in 2023, then surged by 48.45% to $488.7 million in 2024.